We found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitlePhase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.AuthorsMunster, P N; Marchion, D; Thomas, S; Egorin, M; Minton, S; Springett, G; Lee, J-H; Simon, G; Chiappori, A; Sullivan, D; Daud, AAbstractHistone deacetylase inhibitors (HDACi) can sensitise cancer cells to topoisomerase inhibitors by increasing their access and binding to DNA.PublicationBritish journal of cancer, 2009, Vol 101, Issue 7, p1044ISSN1532-1827Publication typeJournal ArticleDOI10.1038/sj.bjc.6605293